GLP-1 receptor agonist
A GLP-1 receptor agonist registered for type 2 diabetes and chronic weight management.
Among the best-evidenced peptides covered here: large randomised trials support its registered diabetes and weight-management indications. That evidence applies to the approved, brand-name products.
Common side effects are gastrointestinal (nausea, vomiting, constipation). Prescribers weigh contraindications and monitor use. "Compounded semaglutide" and online copies sit outside that assurance and have drawn regulator warnings.
A registered prescription medicine in Australia under defined brand names and indications. Supply is via prescription and dispensing pharmacy.
Lawful access is via a prescription from a registered doctor and dispensing through a pharmacy, subject to availability. PBS subsidy applies only to specific criteria.
Yes — registered brand-name semaglutide is a lawful prescription medicine. The caution is around unapproved "compounded" or online versions, which are a different regulatory question.
Subsidy applies only to specific registered indications and criteria. Many weight-management uses are private-script and not PBS-subsidised. A prescriber can confirm your situation.
This entry is general information about Semaglutide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.